Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCELERATE: Accelerated ART Initiation Protocol for People With HIV Out of Care
NCT06374758Phase 4Active, not recruiting
- Sponsor
- University of Missouri
- Start
- Apr 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by University of Missouri. Started Apr 2024; status: active, not recruiting.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06374758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374758.